ProBioGen and LAVA Therpuetics N.V. have closed a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA’s pipeline.
Under the agreement and using its CHO.RiGHT expression platform, including its DirectedLuck Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel gamma-delta bsTCE.
Dr. Lutz Hilbrich, ProBioGen’s Chief Executive Officer, said: “We are delighted to continue our collaboration with LAVA to develop cell lines for another novel gamma-delta bsTCE. Our proven cell line development platform, which also includes our Transposase technology, is perfectly suited for novel protein formats.”
Stephen Hurly, Chief Executive Officer and President of LAVA Therapeutics, commented: “Based on the great results from our previous agreement, we would look forward working with ProBioGen again. ProBioGen exceeded our expectations and proved to be a scientifically driven partner with a proven development platform and a dedicated analytical panel for bispecific antibody formats.”